Patent intelligence · WO
WO 2013133980
DÉRIVÉS NITROXY DE STÉROÏDES DOUX
DÉRIVÉS NITROXY DE STÉROÏDES DOUX
Patent details — WO 2013133980
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Sep 12, 2013
- Expiration
- Sep 7, 2033
- Applicant
- BAUSCH & LOMB [US]
- CPC classes
- A61K 31/ 573 A I, A61P 5/ 44 A I, A61P 27/ 14 A I, A61P/2714
Quick answer
WO 2013133980 (DÉRIVÉS NITROXY DE STÉROÏDES DOUX) is held by BAUSCH & LOMB [US]. Status: granted. Granted Sep 12, 2013. Expires Sep 7, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAUSCH & LOMB [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 573 A I, A61P 5/ 44 A I, A61P 27/ 14 A I, A61P/2714, A61P/544
More from BAUSCH & LOMB [US]
Related pharmaceutical patents in our USPTO index.
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
US 2019151500
OPHTHALMIC VISCOELASTIC COMPOSITIONS
granted -
CA 3043000
DERIVES DE PROSTAGLANDINE LIBERANT DE L'OXYDE NITRIQUE POUR LE TRAITEMENT DU GLAUCOME A TENSION NORMALE
granted -
US 2016213609
OPHTHALMIC SUSPENSION COMPOSITION
granted -
US 2015038439
METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS
granted -
US 2014206764
Poly(Nitrogen/Amine) Derivatives of a Natural Wax and Ophthalmic Compositions
granted -
US 2014142182
Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
granted
Frequently asked questions
What is US patent 2013133980?
WO 2013133980 (DÉRIVÉS NITROXY DE STÉROÏDES DOUX) is held by BAUSCH & LOMB [US]. Status: granted. Granted Sep 12, 2013. Expires Sep 7, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2013133980?
BAUSCH & LOMB [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2013133980 expire?
Our index shows an expiration date of Sep 7, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.